These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 16282845)

  • 1. Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: a preliminary blind-rater study.
    Dannon PN; Lowengrub K; Musin E; Gonopolski Y; Kotler M
    J Clin Psychopharmacol; 2005 Dec; 25(6):593-6. PubMed ID: 16282845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 12-month follow-up study of drug treatment in pathological gamblers: a primary outcome study.
    Dannon PN; Lowengrub K; Musin E; Gonopolsky Y; Kotler M
    J Clin Psychopharmacol; 2007 Dec; 27(6):620-4. PubMed ID: 18004130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topiramate versus fluvoxamine in the treatment of pathological gambling: a randomized, blind-rater comparison study.
    Dannon PN; Lowengrub K; Gonopolski Y; Musin E; Kotler M
    Clin Neuropharmacol; 2005; 28(1):6-10. PubMed ID: 15711432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does sustained-release lithium reduce impulsive gambling and affective instability versus placebo in pathological gamblers with bipolar spectrum disorders?
    Hollander E; Pallanti S; Allen A; Sood E; Baldini Rossi N
    Am J Psychiatry; 2005 Jan; 162(1):137-45. PubMed ID: 15625212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling.
    Kim SW; Grant JE; Adson DE; Shin YC
    Biol Psychiatry; 2001 Jun; 49(11):914-21. PubMed ID: 11377409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended observation of reduced methamphetamine use with combined naltrexone plus bupropion in the ADAPT-2 trial.
    Li MJ; Chau B; Belin T; Carmody T; Jha MK; Marino EN; Trivedi M; Shoptaw SJ
    Addiction; 2024 Oct; 119(10):1840-1845. PubMed ID: 38856086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges.
    Grant JE; Kim SW; Hartman BK
    J Clin Psychiatry; 2008 May; 69(5):783-9. PubMed ID: 18384246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity.
    Padwal R
    Curr Opin Investig Drugs; 2009 Oct; 10(10):1117-25. PubMed ID: 19777400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo.
    Greenway FL; Dunayevich E; Tollefson G; Erickson J; Guttadauria M; Fujioka K; Cowley MA;
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4898-906. PubMed ID: 19846734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity.
    Halseth A; Shan K; Walsh B; Gilder K; Fujioka K
    Obesity (Silver Spring); 2017 Feb; 25(2):338-345. PubMed ID: 28026920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomised, Double-Blind, Placebo-Controlled Trial of As-Needed Naltrexone in the Treatment of Pathological Gambling.
    Kovanen L; Basnet S; Castrén S; Pankakoski M; Saarikoski ST; Partonen T; Alho H; Lahti T
    Eur Addict Res; 2016; 22(2):70-9. PubMed ID: 26339899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bupropion in the treatment of pathological gambling: a randomized, double-blind, placebo-controlled, flexible-dose study.
    Black DW; Arndt S; Coryell WH; Argo T; Forbush KT; Shaw MC; Perry P; Allen J
    J Clin Psychopharmacol; 2007 Apr; 27(2):143-50. PubMed ID: 17414236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use Disorder.
    Mooney LJ; Hillhouse MP; Thomas C; Ang A; Sharma G; Terry G; Chang L; Walker R; Trivedi M; Croteau D; Sparenborg S; Ling W
    J Addict Med; 2016; 10(4):236-43. PubMed ID: 27379819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathological gambling: comorbid psychiatric diagnoses in patients and their families.
    Dannon PN; Lowengrub K; Aizer A; Kotler M
    Isr J Psychiatry Relat Sci; 2006; 43(2):88-92. PubMed ID: 16910370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting response to opiate antagonists and placebo in the treatment of pathological gambling.
    Grant JE; Kim SW; Hollander E; Potenza MN
    Psychopharmacology (Berl); 2008 Nov; 200(4):521-7. PubMed ID: 18581096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain.
    Toll BA; Leary V; Wu R; Salovey P; Meandzija B; O'Malley SS
    Addict Behav; 2008 Jan; 33(1):173-9. PubMed ID: 17587504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination therapy with naltrexone and bupropion for obesity.
    Billes SK; Greenway FL
    Expert Opin Pharmacother; 2011 Aug; 12(11):1813-26. PubMed ID: 21689063
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
    Apovian CM; Aronne L; Rubino D; Still C; Wyatt H; Burns C; Kim D; Dunayevich E;
    Obesity (Silver Spring); 2013 May; 21(5):935-43. PubMed ID: 23408728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Greenway FL; Fujioka K; Plodkowski RA; Mudaliar S; Guttadauria M; Erickson J; Kim DD; Dunayevich E;
    Lancet; 2010 Aug; 376(9741):595-605. PubMed ID: 20673995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid antagonist naltrexone for the treatment of pathological gambling in Parkinson disease.
    Bosco D; Plastino M; Colica C; Bosco F; Arianna S; Vecchio A; Galati F; Cristiano D; Consoli A; Consoli D
    Clin Neuropharmacol; 2012; 35(3):118-20. PubMed ID: 22426027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.